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Astman ja keuhkoahtaumataudin esiintyminen samanaikaisesti tietyillä potilailla on noussut tutkimuksen 
kohteeksi vasta hiljattain. Niin sanottu “asthma COPD overlap” (ACO) on suhteellisen uusi termi eikä 
yhdenmukaista diagnostista kriteeristöä tai hoitosuositusta ole vielä pystytty laatimaan. On myös 
epäselvää, mitä ja kuinka paljon astmaan liittyviä ominaisuuksia keuhkoahtaumatautipotilallla esiintyy. 
Tähän tutkimukseen otettiin mukaan 64 potilasta, joilla kaikilla oli vähintään kymmenen askivuoden 
tupakointihistoria, spirometriassa FEV1/FVC keuhkoputkia laajentavan lääkkeen jälkeen alle 0,70 sekä 
radiologisesti todettu keuhkoemfyseema. Yhdelläkään potilaista ei ollut aiempaa astmadiagnoosia. Tämän 
tutkimuksen tarkoituksena oli selvittää erilaisten astmaan liittyvien piirteiden esiintyvyyttä potilailla, joilla 
on entuudestaan varma keuhkoahtaumatautidiagnoosi.  
Uloshengityksestä mitattu typpioksidipitoisuus > 50 ppb sekä merkittävä vuorokausivaihtelu kahden viikon 
PEF-seurannassa esiintyivät aineistossamme 4,7 % potilaista. Veren seerumista mitattu IgE > 100 IU/l 
esiintyi jopa 47,4 % potilaista. Muiden mitattujen ominaisuuksien esiintyvyydet jakautuivat näiden kahden 
arvon välille. Aineiston potilaista 44 % sai merkittävän FEV1-vasteen hengitettävästä β2-agonistista. Heidän 
sekuntikapasiteettinsa ennen keuhkoputkia laajentavaa lääkitystä oli merkittävästi matalampi (48.9 (12.9) 
vs 57.4 (15.7) % pred, p=0.023) ja he saivat vasteen hengitettävästä kortikosteroidilääkityksestä useammin 
(37.0 vs. 6.3 %, p = 0.003) kuin potilaat, jotka eivät reagoineet merkittävästi keuhkoputkia avaavaan 
lääkitykseen. Veren eosinofiilisillä valkosoluilla ei ollut yhteyttä vasteeseen hengitettävälle β2-agonistille. 
Astmaan liittyviä ominaisuuksia esiintyy keuhkoahtaumatautia saiarastavilla potilailla hyvin paljon. Tästä 
syystä diagnostiikan ja hoitosuositusten taustalla ei tulisi kyttää yksittäisiä kriteereitä, vaan perustaa 
päätökset useisiin löydöksiin ja suhtautua potilaaseen ja tämän oireisiin kokonaisuutena. 
 
Tämän opinnäytteen alkuperäisyys on tarkastettu Turnitin OriginalityCheck-ohjelmalla Tampereen 
yliopiston laatujärjestelmän mukaisesti.  
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Abstract 
Asthma-COPD overlap (ACO) is a relatively new entity without uniform diagnostic protocol. Different criteria 
of ACO have been presented, but it is not known how prevalent these features are and how they are related 
to each other among subjects with COPD. 
We recruited 64 subjects with COPD (smoking history ≥ 10 pack-years, post-bronchodilator FEV1/FVC<0.70, 
emphysema of the lung, no previous diagnosis of asthma) and studied the prevalence of different features 
of ACO or asthma among these subjects. 
The prevalence of asthma-like features among the subjects with COPD varied between 4.7 % (FeNO > 50 ppb 
and significant diurnal variation in peak flow monitoring) and 47.4 % (serum IgE > 100 IU/l). Forty-four % of 
the subjects had significant response to β2-agonists in FEV1 and they had lower baseline pre-bronchodilator 
FEV1 (48.9 (12.9) vs 57.4 (15.7) % pred, p=0.023) but more often significant response to inhaled fluticasone 
treatment (37.0 vs. 6.3 %, p = 0.003). Blood eosinophil count was not associated with response to β2-agonists. 
Different criteria of ACO, especially those concerning responsiveness to β2-agonists, are frequently fulfilled 
among subjects with COPD and therefore diagnosis of ACO or asthma in these subjects should not be based 
on any single feature. 
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Introduction 
 
Both chronic obstructive pulmonary disease (COPD) and asthma are very common diseases among general 
population. Globally about 175 and 360 million people are estimated to have COPD and asthma, respectively 
(1). Prevalence of COPD is about 10 % among adults aged 40 years or more (2) while the prevalence of asthma 
is even higher in many western countries (3). 
Approximately 20 % of the patients with COPD also have symptoms associated with asthma (4, 5). This 
asthma-COPD overlap (ACO) is a relatively new term and it is not clear whether it is a combination of the two 
diseases or a separate condition. A key feature of ACO is a chronic bronchial obstruction as in COPD with 
asthma-like features such as partial reversibility and some degree of responsiveness to inhaled corticosteroid 
(ICS) treatment (4, 6). Patients with ACO have poorer quality of life, higher mortality rate and greater risk of 
hospitalisation when compared to patients with only COPD or asthma (4-8). Due to its very heterogeneous 
nature, knowledge of various pharmacological interventions for treating ACO is very limited (9). Also, COPD 
patients with features of asthma and asthma patients with features of COPD are usually excluded from 
pharmacological studies further diminishing our knowledge on treatment responses in subjects with ACO. 
Different criteria for diagnosing ACO have been presented but still there is no uniform consensus. The Global 
Initiatives for Asthma (GINA) and COPD (GOLD) have a joint project to provide guidelines for diagnosing 
patients with ACO (10, 11). This GINA/GOLD guideline presents ACO as a condition featuring persistent 
bronchial obstruction with several properties usually associated with asthma and several properties usually 
associated with COPD. These properties include, for example, patient’s history of respiratory diseases and 
smoking, respiratory symptoms as well as characteristic lung function for either asthma or COPD in 
spirometry. 
Some national guidelines on asthma or COPD have presented their own somewhat divergent criteria for ACO 
(12-15). Different criteria used to define ACO in clinical studies or guidelines were reviewed recently (16) 
showing considerable variation. A recent consensus published by Sin et al. introduces a series of major and 
minor criteria to identify patients with ACO from those with asthma or COPD. (17) According to the 
committee a diagnosis of ACO requires fulfilment of all of the three major criteria (significant persistent 
airway obstruction in patient aged 40 years or older, a history of smoking at least 10 pack-years or an 
equivalent exposure to air pollution, a history of asthma before the age of 40 or a significant response in FEV1 
to inhaled β2-agonists) and at least one of the three minor criteria (documented history of atopy, a 
bronchodilator response in FEV1 ≥ 200 ml and 12 %, elevated blood eosinophil count). 
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None of the guidelines for diagnosing ACO are based on solid scientific evidence and it is not known how 
large proportion of subjects with COPD fulfils different individual criteria of ACO. The aim of this study was 
to compare among subjects with definite COPD the prevalence of different features proposed as criteria for 
ACO and to study how these features differ in subjects with or without responsiveness to β2-agonists or 
according to blood eosinophil count. 
 
 
Material and methods 
 
Subjects 
 
We recruited 64 patients with suspected COPD who were referred from primary care to the Department of 
Respiratory Diseases at Tampere University Hospital (18). The inclusion criteria were a smoking history of at 
least 15 pack-years, symptoms compatible with COPD, post bronchodilation FEV1/FVC < 0.70 and emphysema 
visible on high resolution CT of lungs. Exclusion criteria were a previous diagnosis of asthma, COPD or any 
other chronic lung disease, and arterial oxygen tension less than 8.0 kPa. Only reliever medication with short-
acting β2–agonists was allowed during the measurements. Possible previous treatments with inhaled 
corticosteroids (ICS), leukotriene antagonists, long-acting bronchodilators or theophylline were withdrawn 
for at least 4 weeks before the first measurements. The study was approved by the Ethics Committee of 
Tampere University Hospital and all subjects gave their written informed consent. 
 
Study protocol 
 
Spirometry (Vmax 20C, SensorMedics, Yorba Linda, CA, USA) was measured and a two-week home peak 
expiratory flow (PEF) monitoring was conducted. Exhaled nitric oxide at flow rate of 50 ml/s (FeNO) was 
measured (Sievers NOA280, Boulder, Colorado) (19). Blood eosinophil count and serum level of IgE were 
analysed. While the subjects were lying in supine position and performing full inspiration, high resolution 
computed tomography (HRCT) of the lungs was scanned (Siemens Somatom Plus 4, Siemens Medical, 
Erlangen, Germany; a section thickness of 1 mm was used with a 10 mm inter-slice spacing at 140 kV and 206 
mAs) to assess the presence of emphysema. The same measurements excluding PEF-monitoring and HRCT 
were repeated after 4 weeks of treatment with inhaled fluticasone propionate (Flixotide Diskus 500 μg b.i.d., 
GlaxoSmithKline, Ware, UK). 
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Statistics 
 
All the data were analyzed using SPSS statistics version 23 (IBM, USA). Data is presented as percentages, 
mean (SD) or as median [inter-quartile range]. Comparisons between groups were analyzed with 
independent sample T-test or median test for continuous variables. Chi2-test or Fischer’s exact test were used 
to compare differences between groups in categorical variables. 
 
 
Results 
 
The basic characteristics of our sample of patients can be found in table 1. The subjects were mostly male 
and mostly active smokers with an average smoking history of 42.3 pack-years. Majority of the subjects had 
a GOLD stage 2 or 3 obstruction. Only 11 % of the subjects were on regular ICS treatment at enrollment and 
this was stopped four weeks before the measurements. 
The prevalence of different features regarded as criteria for asthma or ACO in different guidelines are shown 
in table 2. Prevalence of asthma-like features varied between 4.7 % (FeNO > 50 ppb and significant diurnal 
variation in 2 weeks PEF-monitoring) and 47.4 % (serum IgE > 100 IU/l). The prevalence of reversibility to β2-
agonists varied from 15.6 to 43.8 % depending on the criterion. Approximately 10 % of the subjects had blood 
eosinophil count higher than 0.45 x 109/l. 
Table 3 presents the results by dividing the subjects to those with and without significant β2-agonist induced 
change in FEV1. Those with significant partial reversibility had poorer baseline lung function and the 
proportion of ex-smokers was higher. As expected, those with significant reversibility in spirometry had also 
higher mean response to β2-agonists during PEF monitoring, but interestingly there was no difference in 
spontaneous diurnal variation in PEF between the groups. The subjects with significant response to β2-
agonists were also more often responsive to inhaled fluticasone (defined as improvement in pre-
bronchodilator FEV1 at least 12 % and 200 ml). 
In table 4 we divided the subjects into two groups using a 0.20 x 109/l cut point for blood eosinophils. Subjects 
with blood eosinophil over this cut-point had a higher median value of serum total IgE level (33. 0 vs 23.5 
IU/l, p = 0.027) and they more often fulfilled the criterion of having IgE level higher than 100 IU/l (vs. 16 (61.5 
%) vs. 9 (30 %), p = 0.023) as compared to subjects with blood eosinophil below 0.20 x 109/l. The same 
calculations were also conducted using cut points of 0.15, 0.30 and 0.40 x 109/l. However, there were no 
significant differences in any parameters between the groups using these cut points (data not shown). 
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Table 1. Subject characteristics of the patients with COPD. 
 All subjects 
N 64 
post b.d. FEV1/FVC < 0.7 64 (100 %) 
Smoking history ≥ 15 pack-years 64 (100 %) 
Emphysema visible on HRCT 64 (100 %) 
Age, years 58.3 (8.0) 
Males/Females 47 (73.4 %) / 17 (26.6 %) 
Regular ICS treatment before enrollment 7 (11 %) 
Current/Ex-smokers 49 (76.6%) / 15 (23.4%) 
Pack-years 42.3 (16.1) 
Post b.d. FEV1, L 2.1 (0.6) 
Post b.d. FEV1 ,% pred 60.8 % (15.3 %) 
Percentage reversibility in FEV1, % 14.8% (14.3) 
GOLD-classes 1/2/3/4, n 5 / 46 / 12 / 1 
St George Respiratory Questionnaire total 
score 
33.5 (15.7) 
Blood eosinophil count, x109/L 0.19 [0.11 – 0.28] 
Serum total IgE, IU/L 95 [31 – 228] 
FENO0.05, ppb 9.9 [5.7 – 15.7] 
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Table 2. Proportions of subjects with COPD fulfilling different proposed criteria for ACO or asthma (n=64). 
GI
N
A 
/ G
O
LD
 lu
ng
 
fu
nc
tio
n 
cr
ite
ria
 fo
r A
CO
 post b.d. FEV1/FVC < 0.7 64 (100 %) 
post b.d. FEV1 < 80 % 
predicted 
59 (92 %) 
FEV1 reversibility ≥ 12 % and 
200 ml 
(n) 
28 (43.8%) 
FEV1 reversibility ≥ 12 % and 
400 ml 
(n) 
11 (17.2%) 
GI
N
A 
lu
ng
 fu
nc
tio
n 
cr
ite
ria
 fo
r a
st
hm
a 
(if
 n
ot
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e)
 
FEV1 reversibility ≥ 15 % and 
400 ml 
(n) 
10 (15.6 %) 
Average daily PEF-
variability* > 10 % over 2 
weeks 
15 out of 61 (24.6%) 
Increase in pre b.d. FEV1 ≥ 
12 % and 200 ml after 4 
weeks of inhaled 
fluticasone 
8 out of 44 (18.2 %) 
Increase in post b.d. FEV1 ≥ 
12 % and 200 ml after 4 
weeks of inhaled 
fluticasone 
11 out of 41 (26.8 %) 
O
th
er
 c
rit
er
ia
 fo
r A
CO
 (i
f n
ot
 
pr
es
en
te
d 
al
re
ad
y 
ab
ov
e)
 
Significant β2-agonist 
induced reversibility in 2 
weeks PEF-monitoring**  
(n) 
28 (43.8%) 
Significant diurnal variation 
in 2 weeks PEF-
monitoring*** 
(n)  
3 (4.7%) 
 
Blood eosinophil count > 
0.45 x∙109/l 
6 out of 56 (10.7 %) 
Serum total IgE level > 100 
IU 
27 out of 57 (47.4 %) 
FENO0.05 > 50 ppb 3 (4.7%) 
*calculated as (day’s highest PEF – day’s lowest PEF)/(mean of day’s highest and lowest PEF) averaged over 
two weeks 
**β2-agonist induced improvement in PEF at least 60 l/min and 15 % on at least 3 occasions during the 2 
weeks calculated as (post β2-agonist PEF – pre β2-agonist PEF)/(pre β2-agonist PEF) 
***diurnal variation in PEF at least 60 l/min and 20 % on at least 3 occasions during the 2 weeks calculated 
as (day’s highest PEF – day’s lowest PEF)/(mean of day’s highest and lowest PEF) 
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Table 3. Differences in clinical features between subjects with and without significant β2-agonist induced 
change in spirometry. 
 β2-agonist induced 
change in FEV1 < 12 % 
and 200 ml 
β2-agonist induced 
change in FEV1 ≥ 12 % 
and 200 ml 
p-value 
n (%) 36 (56.3 %) 28 (43.7 %) n.a. 
Males, n (%) 26 (72.2 %) 21 (75.0 %) 0.803 
Regular ICS treatment 
before enrollment, n (%) 
4 (11.1 %) 3 (10.7 %) 0.960 
Age, years 57.6 (7.7) 59.3 (8.4) 0.385 
BMI, kg/m2 24.6 (4.4) 26.3 (4.5) 0.137 
St George Respiratory 
Questionnaire total 
score 
34.9 (16.7) 31.9 (14.5) 0.457 
Pack-years 42.3 (20.1) 42.2 (9.1) 0.981 
Current smokers / ex-
smokers, n (%) 
32 (88.9 %) / 4 (11.1 %) 17 (60.7 %) / 11 (39.3 
%) 
0.008 
FEV1 pre b.d., l 2.0 (0.6) 1.7 (0.6) 0.084 
FEV1 pre b.d., % 
predicted 
57.4 (15.7) 48.9 (12.9) 0.023 
FEV1 post b.d., l 2.1 (0.7) 2.1 (0.6) 0.928 
FEV1 post b.d., % 
predicted 
60.9 (16.5) 60.8 (13.7) 0.985 
Mean β2-agonist 
induced change in PEF 
during two weeks 
follow-up, % 
9.5 (6.4) 13.6 (5.6) 0.009 
Mean diurnal PEF-
variation, % 
7.7 (4.6) 8.4 (4.1) 0.504 
Mean diurnal PEF-
variation > 10 % 
8 (24.2 %) 7 (25.0 %) 0.945 
Increase in pre b.d. FEV1 
≥ 12 % and 200 ml after 
4 weeks of inhaled 
fluticasone 
2 (6.3 %) 10 (37.0 %) 0.003 
Increase in post b.d. 
FEV1 ≥ 12 % and 200 ml 
after 4 weeks of inhaled 
fluticasone 
6 (24.0 %) 6 (33.3 %) 0.501 
Blood eosinophil count, 
109/l 
0.21 [0.08 – 0.28] 0.17 [0.13 – 0.30] 0.789 
Blood eosinophil count > 
0.45 x∙109/l 
3 (10.0 %) 3 (11.5 %) 0.853 
Serum total IgE level, 
IU/l 
106 [30 – 264] 80 [29 – 174] 0.885 
Serum total IgE level > 
100 IU/l 
16 (51.6 %) 11 (42.3 %) 0.483 
FENO0.05, ppb 9.7 [5.5 – 12.9] 11.6 [6.4 – 23.6] 0.801 
FENO0.05 > 50 ppb 0 (0 %) 3 (10.7 %) 0.079 
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Table 4. Clinical features in subjects divided into two groups based on blood eosinophil counts using a cut 
point of 0.20 x 109/l 
 Blood eosinophils < 0.20 x 
109/l  
Blood eosinophils ≥ 0.20 x 
109/l 
p-value 
N 30 26 n.a. 
Females / males, n (%) 10 (33.3 %) / 20 (66.7 %) 5 (19.2 %) / 21 (80.8 %) 0.235 
Regular ICS treatment 
before enrollment, n (%) 
4 (13.3 %) 3 (11.5 %) 1.000 
Age, years 60.0 (8.4) 58.0 (7.0) 0.334 
BMI, kg/m2 24.4 (4.0) 26.4 (4.9) 0.110 
St George Respiratory 
Questionnaire total score 
34.1 (13.6) 34.4 (17.2) 0.942 
Pack-years 42.3 (15.4) 44.2 (17.9) 0.673 
Current smokers / ex-
smokers, n (%) 
21 (70.0 %) / 9 (30.0 %) 22 (84.6 %) / 4 (15.4 %) 0.196 
FEV1 pre b.d., l 1.8 (0.6) 1.9 (0.6) 0.475 
FEV1 pre b.d., % predicted 54.3 (16.2) 52.0 (14.7) 0.589 
FEV1 post b.d., l 2.0 (0.7) 2.2 (0.7) 0.389 
FEV1 post b.d., % predicted 61.8 (15.9) 59.3 (15.6) 0.669 
Mean β2-agonist induced 
change in PEF during two 
weeks follow-up, % 
12.7 (6.8) 10.6 (5.8) 0.226 
Mean diurnal PEF-
variation, % 
8.1 (4.2) 8.0 (4.6) 0.946 
Mean diurnal PEF-
variation > 10% 
6 (20.0%) 6 (23.1%) 0.709 
Percentage reversibility in 
FEV1, % 
16.0 (15.9) 15.1 (12.8) 0.807 
Increase in pre b.d. FEV1 ≥ 
12 % and 200 ml after 4 
weeks of inhaled 
fluticasone 
5 (16.7 %) 6 (23.1 %) 0.582 
Increase in post b.d. FEV1 ≥ 
12 % and 200 ml after 4 
weeks of inhaled 
fluticasone 
7 (23.3 %) 4 (15.4 %) 1.000 
β2-agonist induced change 
in FEV1 ≥ 12 % and 200 ml 
15 (50.0 %) 11 (42.3 %) 0.565 
β2-agonist induced change 
in FEV1 ≥ 12 % and 400 ml 
5 (16.7 %) 5 (19.2 %) 1.000 
β2-agonist induced change 
in FEV1 ≥ 15 % and 400 ml 
4 (13.3 %) 5 (19.2 %) 0.719 
Serum total IgE level, IU/l 62 [15 – 123] 135 [53 – 266] 0.027 
Serum total IgE level > 100 
IU/l 
9 (30 %) 16 (61.5 %) 0.023 
FENO0.05, ppb 9.8 [5.3 – 14.6] 10.9 [7.4 – 24.3] 0.243 
FENO0.05 > 50 ppb 0 (0 %) 3 (11.5 %) 0.094 
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Discussion 
 
We found in subjects with well characterized COPD a great variation in how many subjects fulfill different 
criteria for ACO or asthma. Subjects with significant β2-agonist induced reversibility in spirometry tend to 
have poorer pre-bronchodilator lung function and better response to inhaled corticosteroids but there were 
no differences between the groups in other parameters usually associated with asthma, such as blood 
eosinophil count, serum total IgE level, FeNO or diurnal variation of PEF. Higher blood eosinophil count was 
associated with higher serum total IgE level but not to other criteria of ACO. 
We found that the prevalence of asthma-like features varied between 4.7 % (FeNO > 50 ppb and significant 
diurnal variation in 2 weeks PEF-monitoring) and 47.4 % (serum IgE > 100 IU/l) among subjects with definite 
COPD. Other studies have reported that depending on the criteria used as many as 6 – 27 % of subjects with 
COPD fulfill also criteria for ACO (20, 21). On the other hand, about 20 % of subjects with adult-onset asthma 
have been shown to have a significant smoking history and fixed airway obstruction compatible with ACO 
(22). These findings highlight similarities between subjects labeled as having asthma or COPD. Due to vague 
nature of these diagnostic labels and presence of many underlying endotypes, it may be that finding treatable 
traits and diagnosing patients accordingly would lead to better clinical outcomes and characterization than 
using labels like asthma, COPD and ACO (23). 
Significant reversibility in FEV1 in response to β2-agonist is a feature commonly associated with asthma (10). 
However, a considerable proportion of subjects with COPD have been reported to have significant acute 
response to bronchodilators (24). Interestingly subjects with significant β2-agonist induced reversibility in 
FEV1 in our study had more often a positive response to ICS in pre-bronchodilator lung function. An obvious 
explanation would be that responsiveness to β2-agonists would be a marker of eosinophilic steroid-sensitive 
inflammation and thus ICS responsiveness. However, there was no difference in blood eosinophil count 
between subjects with or without responsiveness to β2-agonist. Further, change in post-bronchodilator FEV1 
after ICS treatment was not different according to responsiveness to β2-agonists. In baseline, pre-
bronchodilator lung function was lower but post-bronchodilator lung function was similar in subjects with 
responsiveness to β2-agonists as compared to those without. It seems thus that responsiveness to β2-agonists 
is not a reliable marker of eosinophilic inflammation or response to ICS, but merely reflects random variation 
in smooth muscle constriction in subjects with COPD. Those subjects who happen to have smooth muscle 
constriction at the time of spirometry have lower pre-bronchodilator lung function, significant response to 
β2-agonist but similar post-bronchodilator lung function as compared to those subjects who happened to 
have less smooth muscle constriction at the moment of spirometry. This is supported by previous findings in 
large follow-up studies showing that at each visit roughly 25 % of subjects with COPD show significant 
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responsiveness to β2-agonists but this is not a fixed characteristic but varies between individuals at each visit 
(25). 
In some set of criteria for ACO also markers of type 2 inflammation have been included (12). In the current 
study, almost half of the patients fulfilled the criterion of having serum total IgE level at least 100 IU/l. 
However, only about 11 % of the subjects had blood eosinophil count at least 0.45 x 109/l and only about 5 
% had FeNO at least 50 ppb. Since majority of the subjects were still active smokers and smoking is known to 
decrease FeNO (26, 27), it may be that FeNO is not a suitable tool to detect T2-high inflammation in these 
subjects. Blood eosinophil count has recently shown promise as a possible marker of responsiveness to ICS 
in subjects with COPD, but usually the best cut-point has been in the range of 0.15 – 0.3 x 109/l (28), being 
considerably less than the proposed criterion for ACO. This may be one of the reasons for a low proportion 
of subjects fulfilling the criterion of eosinophil count at least 0.45 x 109/l in the present study. 
It is established in many studies that COPD patients with high eosinophil count or “atopic phenotype” 
respond better to ICS treatment than their peers with a lower eosinophil count (29-31). In our study higher 
blood eosinophil count correlated with higher IgE level in the blood which is logical as they are both 
associated with type 2 inflammation. However, in the current study there was no difference in response to 
ICS treatment in regards of improvement in FEV1 between groups of high or low blood eosinophil count. This 
is in line with previous studies suggesting that high blood eosinophil count would best predict the ability of 
ICS to reduce the number of exacerbations in COPD rather than the ability of ICS to improve lung function 
(28). However, the small number of subjects in the present study of course diminishes statistical power to 
detect differences in treatment responses between the groups. 
A strength of our study is the group of well characterized subjects. All the subjects had a reliable diagnosis of 
COPD according to a well-defined smoking history, permanent obstruction (post-bronchodilator FEV1/FVC 
<0.70), radiologically evaluated emphysema and the series of lung function tests. Also, none of the patients 
had a previous diagnosis of asthma. An obvious weakness of the study is the relatively small number of 
subjects limiting statistical power. 
In conclusion, some of the features associated to asthma or ACO are quite prevalent in subjects with COPD. 
Especially different criteria of responsiveness to β2-agonists are frequently fulfilled and it is therefore 
important for clinicians to bear in mind that diagnosis of ACO or asthma in subjects with smoking history and 
typical findings of COPD should not be based on a single diagnostic criterium but on a more holistic view. 
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